Nicolas Penel1,2, Jean-Michel Coindre3, Antoine Giraud4, Philippe Terrier5, Dominique Ranchere-Vince6, Françoise Collin7, Sophie L E Guellec8, Céline Bazille9, Marick Lae10, Gonzague de Pinieux11, Isabelle L Ray-Coquard12, Sylvie Bonvalot13, Axel L E Cesne13, Yves-Marie Robin14, Eberhardt Stoeckle15, Maud Toulmonde16, Jean-Yves Blay12. 1. Department of Medical Oncology, Oscar Lambret Center, Lille, France. 2. Methodology Clinical Research Platform, Lille French Comprehensive Cancer Center (SIRIC OncoLille), Lille, France. 3. Department of Biopathology, National Institute of Health and Medical Research (INSERM) Unit 916, Bergonie Institute, University of Bordeaux, Bordeaux, France. 4. Clinical and Epidemiologic Research Unit, INSERM Clinical Investigation Center 1401, Bergonie Institute, Bordeaux, France. 5. Department of Pathology, Gustave Roussy Institute, Villejuif, France. 6. Department of Biopathology, Leon Berard Center, Lyon, France. 7. Department of Pathology, Georges-Francois Leclerc Center, Dijon, France. 8. Department of Pathology, University Cancer Institute of Toulouse-Oncopole, Toulouse, France. 9. Department of Pathologic Anatomy, University Hospital, Caen, Basse-Normandie, France. 10. Department of Pathology, Curie Institute, Paris, France. 11. Department of Pathology, University Hospital of Tours and Francois Rabelais University, Tours, France. 12. Department of Medical Oncology, Leon Berard Center, Lyon, France. 13. Department of Medical Oncology and Surgery, Gustave Roussy Institute, Villejuif, France. 14. Department of Pathology, Oscar Lambret Center, Lille, France. 15. Department of Surgery, Bergonie Institute, Bordeaux, France. 16. Department of Medical Oncology, Bergonie Institute, Bordeaux, France.
Abstract
BACKGROUND: The objective of this study was to describe characteristics at diagnosis and outcomes of adults with soft tissue sarcoma. METHODS: The authors conducted a retrospective multicenter study of 12,262 patients who were treated between January 1980 and 31 December 2013 in French Sarcoma Group centers and enrolled in the "Conticabase." Diagnoses were systematically reviewed by expert pathologists, and entities were classified according to the 2013 World Health Organization classification. Diagnostic characteristics, treatments, and outcomes are described for the entire cohort, for the subgroup of patients with translocation-related sarcomas, and for 9 different histologic subtypes. RESULTS: The results stressed the magnitude of heterogeneity among adult sarcomas. For example, compared with other sarcomas, translocation-related sarcomas (2143 tumors; 20.8%) were associated with a younger age at presentation (40.6 vs 60.0 years; P < .0001), a low rate of predisposing conditions (0.01% vs 22.3%; P < .0001), a higher rate of lymph node involvement (4.7% vs 1.3%; P < .0001), and a higher rate of synchronous metastasis (11.9% vs 6.7%; P < .001); and complete (R0) resection (41.6% vs 31.9%; P < .0001), receipt of (neo)adjuvant radiation therapy (62.6% vs 42.2%; P < .0001), and receipt of (neo)adjuvant chemotherapy (36.6% vs 22.3%; P < .0001) were significantly more frequent. Overall, translocation-related sarcomas were associated with a lower rate of local relapse (18.1% vs 26.0%; P < .0001) but a higher rate of metastatic relapse (42.0% vs 30.7%; P < .0001). CONCLUSIONS: Collaborative efforts are urgently needed to better assess the natural history and management options for every histologic subtype of sarcoma. Cancer 2018;124:1179-87.
BACKGROUND: The objective of this study was to describe characteristics at diagnosis and outcomes of adults with soft tissue sarcoma. METHODS: The authors conducted a retrospective multicenter study of 12,262 patients who were treated between January 1980 and 31 December 2013 in French Sarcoma Group centers and enrolled in the "Conticabase." Diagnoses were systematically reviewed by expert pathologists, and entities were classified according to the 2013 World Health Organization classification. Diagnostic characteristics, treatments, and outcomes are described for the entire cohort, for the subgroup of patients with translocation-related sarcomas, and for 9 different histologic subtypes. RESULTS: The results stressed the magnitude of heterogeneity among adult sarcomas. For example, compared with other sarcomas, translocation-related sarcomas (2143 tumors; 20.8%) were associated with a younger age at presentation (40.6 vs 60.0 years; P < .0001), a low rate of predisposing conditions (0.01% vs 22.3%; P < .0001), a higher rate of lymph node involvement (4.7% vs 1.3%; P < .0001), and a higher rate of synchronous metastasis (11.9% vs 6.7%; P < .001); and complete (R0) resection (41.6% vs 31.9%; P < .0001), receipt of (neo)adjuvant radiation therapy (62.6% vs 42.2%; P < .0001), and receipt of (neo)adjuvant chemotherapy (36.6% vs 22.3%; P < .0001) were significantly more frequent. Overall, translocation-related sarcomas were associated with a lower rate of local relapse (18.1% vs 26.0%; P < .0001) but a higher rate of metastatic relapse (42.0% vs 30.7%; P < .0001). CONCLUSIONS: Collaborative efforts are urgently needed to better assess the natural history and management options for every histologic subtype of sarcoma. Cancer 2018;124:1179-87.
Authors: Ece Canan Sayitoglu; Anna-Maria Georgoudaki; Michael Chrobok; Didem Ozkazanc; Benjamin J Josey; Muhammad Arif; Kim Kusser; Michelle Hartman; Tamara M Chinn; Renee Potens; Cevriye Pamukcu; Robin Krueger; Cheng Zhang; Adil Mardinoglu; Evren Alici; Harry Thomas Temple; Tolga Sutlu; Adil Doganay Duru Journal: Front Immunol Date: 2020-01-28 Impact factor: 7.561